586 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

065IC - AUA Guidelines on Advanced Prostate Cancer

Sunday, May 15, 2022

4:00 PM – 6:00 PM

Location: Room 204

Instructional Course Director(s)

Michael S. Cookson, MD,MHA

Professor and Chair
University of Oklahoma

Instructional Course Faculty(s)

Adam S. Kibel, MD

Elliott Carr Cutler Professor of Surgery, Chief of Urology
Brigham Health, Harvard University
DJ

David F. Jarrard, MD

Professor
University of Wisconsin
Kristen R. Scarpato, MD,FACS,MPH

Vanderbilt University Medical Center

Learning Objectives:

Identify appropriate use of genetic testing and genetic counseling.
Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy.
Discuss the treatments for non-metastatic CRPC and their urologic outcomes.
Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing.

This course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include germline testing, positron emission tomography (PET) imaging, the use of combination androgen deprivation therapy (ADT) in combination with novel androgen axis therapy, and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). The course will also cover non-metastatic CRPC, and treatment for metastatic CRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging salvage therapies for CRPC.